HK25192A - Novel galenical retard form - Google Patents

Novel galenical retard form Download PDF

Info

Publication number
HK25192A
HK25192A HK251/92A HK25192A HK25192A HK 25192 A HK25192 A HK 25192A HK 251/92 A HK251/92 A HK 251/92A HK 25192 A HK25192 A HK 25192A HK 25192 A HK25192 A HK 25192A
Authority
HK
Hong Kong
Prior art keywords
matrix
retard form
novel galenical
percent
weight
Prior art date
Application number
HK251/92A
Other languages
English (en)
Inventor
Czarnecki Wolfgang
Claude Gfeller Jean
Peter Bier Hans
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK25192A publication Critical patent/HK25192A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK251/92A 1984-06-14 1992-04-02 Novel galenical retard form HK25192A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3422083 1984-06-14
DE3442566 1984-11-22

Publications (1)

Publication Number Publication Date
HK25192A true HK25192A (en) 1992-04-10

Family

ID=25822108

Family Applications (1)

Application Number Title Priority Date Filing Date
HK251/92A HK25192A (en) 1984-06-14 1992-04-02 Novel galenical retard form

Country Status (21)

Country Link
AT (1) AT391806B (enrdf_load_html_response)
AU (2) AU587190B2 (enrdf_load_html_response)
BE (1) BE902626A (enrdf_load_html_response)
CA (1) CA1264441A (enrdf_load_html_response)
CY (1) CY1635A (enrdf_load_html_response)
DE (1) DE3520184C2 (enrdf_load_html_response)
DK (1) DK167649B1 (enrdf_load_html_response)
ES (1) ES8702141A1 (enrdf_load_html_response)
FR (1) FR2565822B1 (enrdf_load_html_response)
GB (3) GB2160100B (enrdf_load_html_response)
GR (1) GR851430B (enrdf_load_html_response)
HK (1) HK25192A (enrdf_load_html_response)
HU (1) HU198844B (enrdf_load_html_response)
IE (1) IE58834B1 (enrdf_load_html_response)
IL (1) IL75490A0 (enrdf_load_html_response)
IT (1) IT1200080B (enrdf_load_html_response)
LU (1) LU85946A1 (enrdf_load_html_response)
NL (1) NL194389C (enrdf_load_html_response)
NZ (1) NZ212390A (enrdf_load_html_response)
PT (1) PT80635B (enrdf_load_html_response)
SE (1) SE504583C2 (enrdf_load_html_response)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
WO1989009066A1 (en) * 1988-03-24 1989-10-05 Bukh Meditec A/S Controlled release composition
GR1000270B (el) * 1988-09-30 1992-05-12 Alza Corp Μορφη δοσολογιας για θεραπεια καρδιαγγειακων ασθενειων.
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
DE69739165D1 (de) 1996-07-08 2009-01-29 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
AU5483600A (en) * 1999-06-11 2001-01-02 Jean A. Chmielewski Pharmaceutical materials and methods for their preparation and use
CN1193792C (zh) * 1999-08-04 2005-03-23 山之内制药株式会社 稳定的口服医药组合物
WO2001022940A1 (en) 1999-09-30 2001-04-05 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
AU2002228579B2 (en) * 2001-02-13 2006-07-27 Astrazeneca Ab Novel modified released formulation
US7135436B2 (en) 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
EP1690528A1 (de) 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
CA2670749A1 (en) 2006-12-05 2008-06-12 Landec Corporation Drug delivery
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
WO2010022193A2 (en) 2008-08-20 2010-02-25 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617362A1 (de) * 1967-11-17 1971-03-25 Beiersdorf Ag Verfahren zur Herstellung von Arzneimitteln mit verzoegerter Wirkstoffabgabe in Form von Kapseln
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
GB1504553A (en) * 1975-11-17 1978-03-22 Sandoz Ltd Tablet formulations
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
FI64938C (fi) * 1977-06-20 1984-02-10 Sandoz Ag Foerfarande foer framstaellning av nya terapeutiskt anvaendbara bensoxa- och bensotiadiazolyl-1,4-dihydropyridinderivat
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
EP0001247A1 (en) * 1977-09-14 1979-04-04 Kanebo, Ltd. Pharmaceutical preparation containing nifedipine and a method for producing the same.
DK154607C (da) * 1978-12-21 1989-06-05 Sandoz Ag Fremgangsmaade til fremstilling af en laegemiddelform til oral administration af ergotalkaloider
DE2904310A1 (de) * 1979-02-05 1980-08-07 Boehringer Mannheim Gmbh Formlinge mit retardierter wirkstofffreisetzung und verfahren zu deren herstellung
JPS56115726A (en) * 1980-02-20 1981-09-11 Kaken Pharmaceut Co Ltd Pharmaceutical containing nifedipine
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
DE3270785D1 (en) * 1981-10-29 1986-05-28 Bayer Ag Process for preparing solid fast-releasing drug formulations of dihydropyridines
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung

Also Published As

Publication number Publication date
DE3520184A1 (de) 1985-12-19
GB8727055D0 (en) 1987-12-23
IE58834B1 (en) 1993-11-17
GB2196851B (en) 1989-06-07
AU4348685A (en) 1985-12-19
SE8502950L (sv) 1985-12-15
LU85946A1 (fr) 1986-01-24
SE8502950D0 (sv) 1985-06-13
ES8702141A1 (es) 1987-01-01
AU4454389A (en) 1990-03-22
DK264785D0 (da) 1985-06-12
ATA174885A (de) 1990-06-15
ES544075A0 (es) 1987-01-01
GB2160100A (en) 1985-12-18
GB2196852A (en) 1988-05-11
NL194389B (nl) 2001-11-01
GB8727056D0 (en) 1987-12-23
NL8501578A (nl) 1986-01-02
HU198844B (en) 1989-12-28
HUT40918A (en) 1987-03-30
GB2160100B (en) 1989-06-01
DE3520184C2 (de) 1997-03-13
FR2565822A1 (fr) 1985-12-20
PT80635B (pt) 1987-10-20
SE504583C2 (sv) 1997-03-10
PT80635A (en) 1985-07-01
NL194389C (nl) 2002-03-04
IL75490A0 (en) 1985-10-31
CA1264441A (en) 1990-01-16
NZ212390A (en) 1992-02-25
DK264785A (da) 1985-12-15
AU587190B2 (en) 1989-08-10
IE851460L (en) 1985-12-14
IT1200080B (it) 1989-01-05
FR2565822B1 (fr) 1989-02-17
GB2196851A (en) 1988-05-11
AT391806B (de) 1990-12-10
IT8548210A0 (it) 1985-06-13
GB2196852B (en) 1989-05-17
CY1635A (en) 1992-11-06
BE902626A (fr) 1985-12-10
GR851430B (enrdf_load_html_response) 1985-11-25
GB8514855D0 (en) 1985-07-17
DK167649B1 (da) 1993-12-06

Similar Documents

Publication Publication Date Title
HK25192A (en) Novel galenical retard form
HUT44438A (en) Composition comprising l-dopa
EP0290442A4 (en) MEDICINAL PREPARATIONS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS.
EP0176033A3 (de) Isoxazolcarbonsäure-Derivate, ihre Herstellung und Verwendung
CA2148342A1 (en) Encapsulation with water soluble polymer
CA2118451A1 (en) Inorganic Hardening Composition
NZ213461A (en) 1,4-dihyrdropyridine-3,5-dicarboxylic acid derivatives and pharmaceutical compositions
SE8700137D0 (sv) Diuretisk komposition
HUT38219A (en) Herbicidal compositions comprising delta above 2-1,2,4-triazoline-5-on-derivatives as active substance and process for producing the active substance
IE791107L (en) Anaerobic compositions
JPS55135590A (en) Modified asparaginase and uricase and their preparation
IE800344L (en) Anti-perspirant compositions
MY102425A (en) Preservative for wood
MY101902A (en) Novel galenical retard form
GB2165149B (en) Parenteral composition of dezocine
ATE31076T1 (de) Feste, stark alkalische, aktivchlorhaltige mittel.
AU554432B2 (en) High concentration amine oxide formulations
HUT41233A (en) Insekticide, acaricide and nematocide compositions containing new benzoyl-phenyl-urea derivatives and process for producing the active agents
HUT39978A (en) Pesticide compositions containing pyrimidinyl-thiono-phosphoric acid derivatives as active substabces and process for preparing pyrimidinyl-thiono-phosphoric acid derivatives
JPS5767578A (en) N-phthtalidy-5-fluorouracil derivative
Senczuk et al. Toxicodynamic properties of toluidines. Part V. Methaemoglobin-genic action of toluidines.
CA2141203A1 (en) Amylin muteins
JPS5310896A (en) Cdse humidity sensitive material and its manufacturing process
AU6779487A (en) Pharmacologically active compounds and mixtures thereof, organic compositions and metal salts
Wadhera Organic acid production from xylose and glucose by the yeast Candida utilis.

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20050611